ArticleBMC cancer2018
Droplet digital PCR-based circulating microRNA detection serve as a promising diagnostic method for gastric cancer.
Article in BMC cancer, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 1 synthesis or guideline pooled it, 55 citations in OpenAlex.
- A systematic review of microRNAs as potential biomarkers for diagnosis and prognosis of gastric cancer.Immunogenetics · 2021Pooled it
- Tyrosine-Capped Pt Nanozyme Functionalized with cDNA: An Innovative Sensor Designed for One-Step Detection of the miRNA-21 Biomarker.ACS omega · 2025Article
- Liquid biopsy in gastric cancer: A snapshot of the current state of the art.The journal of liquid biopsy · 2025Review
- Molecular roles of microRNA-21 and exosomal miR-21 in gastrointestinal cancers: diagnostic, therapeutic, and drug resistance insights.Frontiers in molecular biosciences · 2025Review
- Peripherical Blood hsa-miR-335-5p Quantification as a Prognostic, but Not Diagnostic, Marker of Gastric Cancer.Diagnostics (Basel, Switzerland) · 2024Article
- Liquid Biopsy: An Emerging Diagnostic, Prognostic, and Predictive Tool in Gastric Cancer.Journal of gastric cancer · 2024Review
- Circulating microRNA Panels for Detection of Liver Cancers and Liver-Metastasizing Primary Cancers.International journal of molecular sciences · 2023Review
- Novel biomarkers for early detection of gastric cancer.World journal of gastroenterology · 2023Review
- miR-18a and miR-106a Signatures in Plasma Small EVs Are Promising Biomarkers for Early Detection of Pancreatic Ductal Adenocarcinoma.International journal of molecular sciences · 2023Article
- Article
- Knockdown of hsa_circ_0043691 restrains the progression of gastric cancer by decoying miR-1294 to target pre-leukemia transcription factor 3.Journal of clinical laboratory analysis · 2022Article
- DigiMir Test: Establishing a Novel Pipeline for MiR-371a Quantification Using Droplet Digital PCR in Liquid Biopsies From Testicular Germ Cell Tumor Patients.Frontiers in oncology · 2022Article
- Selection of reference genes for quantitative analysis of microRNA expression in three different types of cancer.PloS one · 2022Article
- Systems analysis of miRNA biomarkers to inform drug safety.Archives of toxicology · 2021Review
- Review
- imPlatelet classifier: image-converted RNA biomarker profiles enable blood-based cancer diagnostics.Molecular oncology · 2021Article
- Article
- Circulating MicroRNAs in Gastrointestinal Cancer.Cancers · 2021Review
- A Physically Active Status Affects the Circulating Profile of Cancer-Associated miRNAs.Diagnostics (Basel, Switzerland) · 2021Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
Abstract
backgroundNovel non-invasive biomarkers for gastric cancer (GC) are needed, because the present diagnostic methods for GC are either invasive or insensitive and non-specific in clinic. The presence of stable circulating microRNAs (miRNAs) in plasma suggested a promising role as GC biomarkers.
methodsBased on the quantitative droplet digital PCR (ddPCR), four miRNAs (miR-21, miR-93, miR-106a and miR-106b) related to the presence of GC were identified in plasma from a training cohort of 147 participants and a validation cohort of 28 participants.
resultsAll circulating miRNA levels were significantly higher in the plasma of GC patients compared to healthy controls (P < 0.05). Through a combination of four miRNAs by logistic regression model, receiver operating characteristic (ROC) analyses yielded the highest AUC value of 0.887 in discriminating GC patients from healthy volunteers. Furthermore, miR-21, miR-93 and miR-106b levels were significantly related to an advanced TNM stage in GC patients. ROC analyses of the combined miRNA panel also showed the highest AUC value of 0.809 in discriminating GC patients with TNM stage I and II from stage III and IV. Through combining four miRNAs and clinical parameters, a classical random forest model was established in the training stage. In the validation cohort, it correctly discriminated 23 out of 28 samples in the blinded phase (false rate, 17.8%).
conclusionsUsing the ddPCR technique, circulating miR-21, miR-93, miR-106a and miR-106b could be used as diagnostic plasma biomarkers in gastric cancer patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.